173 related articles for article (PubMed ID: 22356625)
1. Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.
Crouzet L; Edeline J; Le Du F; Boucher E; Audrain O; Raoul JL
Acta Oncol; 2012 May; 51(5):687-8. PubMed ID: 22356625
[No Abstract] [Full Text] [Related]
2. Hemolytic uremic syndrome due to gemcitabine in a young woman with cholangiocarcinoma.
Nieto-Ríos JF; Zuluaga-Quintero M; Higuita LM; Rincón CI; Galvez-Cárdenas KM; Ocampo-Kohn C; Aristizabal-Alzate A; Florez-Vargas AA; Zuluaga-Valencia GA
J Bras Nefrol; 2016 Jun; 38(2):255-9. PubMed ID: 27438981
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.
Lhotta K; Kühr T; Rumpelt HJ; Wöll E; Thaler J; König P
Am J Nephrol; 1999; 19(5):590-3. PubMed ID: 10575189
[TBL] [Abstract][Full Text] [Related]
4. Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma.
Kim SH; Kim IH; Kim SW; Lee SO
World J Gastroenterol; 2009 Sep; 15(36):4593-5. PubMed ID: 19777621
[TBL] [Abstract][Full Text] [Related]
5. Haemolytic uraemic syndrome after gemcitabine treatment for pancreatic carcinoma.
Choi M; Woywodt A; Göbel U; Schneider W; Kettritz R
Nephrol Dial Transplant; 1999 Oct; 14(10):2523-4. PubMed ID: 10528696
[No Abstract] [Full Text] [Related]
6. Gemcitabine and haemolytic-uraemic syndrome.
Ruiz I; Del Valle J; Gómez A
Ann Oncol; 2004 Oct; 15(10):1575-6. PubMed ID: 15367421
[No Abstract] [Full Text] [Related]
7. Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
Kamada M; Akiyoshi K; Akiyama N; Funamizu N; Watanabe M; Fujioka K; Ikeda K; Manome Y
Oncol Rep; 2014 Aug; 32(2):829-34. PubMed ID: 24891233
[TBL] [Abstract][Full Text] [Related]
8. Elevation of urinary porphyrin levels following gemcitabine administration.
Daniele B; De Vivo R
Ann Oncol; 1999 Dec; 10(12):1530-1. PubMed ID: 10643551
[No Abstract] [Full Text] [Related]
9. [Hemolytic uremic syndrome induced by gemcitabine. A poorly recognized complication?].
Graas MP; Houbiers G; Demolin G; Stultiens A; Focan C
Rev Med Liege; 2012 Dec; 67(12):644-8. PubMed ID: 23342875
[TBL] [Abstract][Full Text] [Related]
10. [Long-surviving patient with hilar cholangiocarcinoma by gemcitabine monotherapy].
Iwata N; Yoshida T; Katsuta E; Aoyagi H; Takahata T; Hasegawa K; Kaneko J; Maejima S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2116-8. PubMed ID: 23267995
[TBL] [Abstract][Full Text] [Related]
11. Hemolytic-uremic syndrome caused by gemcitabine.
Nackaerts K; Daenen M; Vansteenkiste J; Vandevelde A; Van Bleyenbergh P; Demedts M
Ann Oncol; 1998 Dec; 9(12):1355. PubMed ID: 9932169
[No Abstract] [Full Text] [Related]
12. Gemcitabine-induced hemolytic uremic syndrome: a case report.
Brodowicz T; Breiteneder S; Wiltschke C; Zielinski CC
J Natl Cancer Inst; 1997 Dec; 89(24):1895-6. PubMed ID: 9414181
[No Abstract] [Full Text] [Related]
13. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
Vogl TJ; Schwarz W; Eichler K; Hochmuth K; Hammerstingl R; Jacob U; Scheller A; Zangos S; Heller M
J Cancer Res Clin Oncol; 2006 Nov; 132(11):745-55. PubMed ID: 16858591
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.
Lee HW; Chung MJ; Kang H; Choi H; Choi YJ; Lee KJ; Lee SW; Han SH; Kim JS; Song SY
Gut Liver; 2014 Jan; 8(1):109-12. PubMed ID: 24516709
[TBL] [Abstract][Full Text] [Related]
15. [Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
Desramé J; Duvic C; Bredin C; Béchade D; Artru P; Brézault C; Defuentes G; Poirier JM; Dourthe LM; Coutant G; Chaussade S; de Gramont A; Algayres JP
Rev Med Interne; 2005 Mar; 26(3):179-88. PubMed ID: 15777580
[TBL] [Abstract][Full Text] [Related]
16. Livedo racemosa and hemolytic uremic syndrome induced by gemcitabine.
Tognetti L; Garosi G; Rongioletti F; Fimiani M; Rubegni P
Int J Dermatol; 2016 Oct; 55(10):e555-6. PubMed ID: 27125732
[No Abstract] [Full Text] [Related]
17. [Is the frequency of hemolytic uremic syndrome as a complication of gemcitabine underestimated? The role of systematic screening].
Desramé J; Duvic C; Béchade D; Bredin C; Raynaud JJ; Defuentes G; Dourthe LM; Algayres JP
Gastroenterol Clin Biol; 2006 Feb; 30(2):332-4. PubMed ID: 16565677
[No Abstract] [Full Text] [Related]
18. Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine.
Petekkaya I; Gezgen G; Roach EC; Solak M; Gullu I
J BUON; 2012; 17(4):796. PubMed ID: 23335544
[No Abstract] [Full Text] [Related]
19. Adjuvant surgery for advanced extrahepatic cholangiocarcinoma.
Oshiro Y; Takahashi K; Sasaki R; Kondo T; Sakashita S; Ohkohchi N
World J Gastroenterol; 2013 Oct; 19(40):6934-8. PubMed ID: 24187473
[TBL] [Abstract][Full Text] [Related]
20. [Hemolytic-uremic syndrome complicating a long-term treatment with gemcitabine. Report of a case and review of the literature].
Dilhuydy MS; Delclaux C; Pariente A; De Precigout V; Aparicio M
Rev Med Interne; 2002 Feb; 23(2):189-92. PubMed ID: 11876063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
